Paradia, Dorotea C.

HRN: 03-48-74  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
02/13/2025
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
02/13/2025
02/20/2025
IV
2.25G
Q8 X7days
CAP
Waiting Final Action 

Indication:  Empiric    Type of Infection:  PneumoniaSkin & Soft Tissue    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: